Harmony Biosciences Holdings, Inc. Financials

Market Capitalization $2.20 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	18.32
Forward PE	11.86
Price to Sales TTM	$3.23
Price to Book MRQ	$3.69
Enterprise to Revenue	2.90
Enterprise to EBITDA	9.92

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	17.98%
Operating Margin	33.17%
Return on Assets TTM	12.85%
Return on Equity TTM	22.75%

Income Statement

Revenue TTM	$681,878,976
Revenue per Share TTM	$11.92
Quarterly Revenue Growth	16.10%
Gross Profit TTM	$536,320,992
EBITDA	$228,324,000
Net Income to Common TTM	$122,625,000
Diluted EPS TTM	$2.11
Quarterly Earnings Growth YoY	19.80%

Balance Sheet

Total Cash MRQ	$410,476,000
Total Cash per Share MRQ	$7.20
Total Debt MRQ	$
Total Debt to Equity MRQ	31.04
Current Ratio MRQ	3.24
Book Value per Share MRQ	$10.47

Cash Flow

Operating Cash Flow TTM	$220,924,000
Levered Free Cash Flow TTM	$168,651,504

HRMY Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	57,031,300
Float Shares	44,055,536
Avg 10 Volume	612,580
Avg 30 Volume	None
Shares Short	5,705,195
Short Ratio	10.08
Short % of Shares	44.13%
% Held by Insiders	11.62%
% Held by Institutions	93.84%

Stock Price Summary

Beta	0.77
Fifty Two Week Low	$28.14
Fifty Two Week High	$41.61
Fifty Two Week Change	15.10%
Day 50 MA	$34.62
Day 200 MA	$33.43

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date